Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GB:0MGB)
LSE:0MGB
0MGB Analyst Ratings
Moderate Buy
5 Buy
2 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0MGB Stock 12 Month Forecast
Average Price Target
kr1,981.38
▲(55.34% Upside)
| Highest Price Targetkr2,700 | Average Price Targetkr1,981 | Lowest Price Targetkr1,000.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bernstein
Downgraded
04/01/25
Barclays
Reiterated
03/12/25
Deutsche Bank
Reiterated
03/11/25
RBC Capital
Reiterated
03/11/25
Bank of America Securities
Reiterated
02/13/25
Exane BNP Paribas
Upgraded
02/11/25
Goldman Sachs
Reiterated
01/27/25
J.P. Morgan
kr2,050→kr1,700
Hold
33.28%
Upside
Reiterated
12/03/24
Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK1,700 at JPMorganJPMorgan analyst James Gordon lowered the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK1,700.00 (from DKK2,050.00) while maintaining a Neutral rating.
Redburn Atlantic
kr2,899
Buy
127.28%
Upside
Initiated
10/08/24
Genmab initiated with a Buy at Redburn AtlanticGenmab initiated with a Buy at Redburn Atlantic
Guggenheim
―
Hold
―
Reiterated
06/27/24
We currently forecast $257M in FY24 sales for Epkinly (vs. $208M consensus) including ~$40M in US sales for 3L+ FL (compared to ~$67M Lunsumio sales in FY23). Longer term, we estimate a peak WW sales opportunity for epco of $2.8B (vs. ~$3B GMAB consensus) coming from label-expansion opportunities in 2L FL and 2L/1L DLBCL, with additional B cell malignancies (i.e., CLL, MCL) representing potential upside to our estimates. We maintain our NEUTRAL rating based on our mixed view on the rest of GMAB's pipeline. Epkinly receives FDA approval for the label expansion into 3L+ FL. The FDA approved SQ Epkinly for treatment of adult patients with r/r FL after two or more lines of systemic therapy with a label that includes data from the Ph.
Citi
kr1,860
Sell
45.83%
Upside
Reiterated
06/04/24
Analysts Offer Insights on Healthcare Companies: Genmab A/S (LSE: GB:0MGB), AstraZeneca (LSE: GB:AZN) and Zur Rose Group AG (Six Swiss: CH:DOCM)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bernstein
Downgraded
04/01/25
Barclays
Reiterated
03/12/25
Deutsche Bank
Reiterated
03/11/25
RBC Capital
Reiterated
03/11/25
Bank of America Securities
Reiterated
02/13/25
Exane BNP Paribas
Upgraded
02/11/25
Goldman Sachs
Reiterated
01/27/25
J.P. Morgan
kr2,050→kr1,700
Hold
33.28%
Upside
Reiterated
12/03/24
Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK1,700 at JPMorganJPMorgan analyst James Gordon lowered the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK1,700.00 (from DKK2,050.00) while maintaining a Neutral rating.
Redburn Atlantic
kr2,899
Buy
127.28%
Upside
Initiated
10/08/24
Genmab initiated with a Buy at Redburn AtlanticGenmab initiated with a Buy at Redburn Atlantic
Guggenheim
―
Hold
―
Reiterated
06/27/24
We currently forecast $257M in FY24 sales for Epkinly (vs. $208M consensus) including ~$40M in US sales for 3L+ FL (compared to ~$67M Lunsumio sales in FY23). Longer term, we estimate a peak WW sales opportunity for epco of $2.8B (vs. ~$3B GMAB consensus) coming from label-expansion opportunities in 2L FL and 2L/1L DLBCL, with additional B cell malignancies (i.e., CLL, MCL) representing potential upside to our estimates. We maintain our NEUTRAL rating based on our mixed view on the rest of GMAB's pipeline. Epkinly receives FDA approval for the label expansion into 3L+ FL. The FDA approved SQ Epkinly for treatment of adult patients with r/r FL after two or more lines of systemic therapy with a label that includes data from the Ph.
Citi
kr1,860
Sell
45.83%
Upside
Reiterated
06/04/24
Analysts Offer Insights on Healthcare Companies: Genmab A/S (LSE: GB:0MGB), AstraZeneca (LSE: GB:AZN) and Zur Rose Group AG (Six Swiss: CH:DOCM)
0MGB Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
4
4
4
5
3
Buy
3
4
4
5
3
Hold
4
5
5
2
1
Sell
0
0
0
1
2
Strong Sell
0
0
0
0
0
total
11
13
13
13
9
Each month's total comprises the sum of three months' worth of ratings.
0MGB Financial Forecast
0MGB Stock Forecast FAQ
What is GB:0MGB’s average 12-month price target, according to analysts?
Based on analyst ratings, Genmab A/S’s 12-month average price target is kr1,981.38.
What is GB:0MGB’s upside potential, based on the analysts’ average price target?
Genmab A/S has 55.34% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Genmab A/S a Buy, Sell or Hold?
Genmab A/S has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 2 hold ratings and 1 sell ratings.
What is Genmab A/S’s share price target?
The average share price target for Genmab A/S is kr1,981.38. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr2,700.00 ,and the lowest forecast is kr1,000.00. The average share price target represents 55.34% Increase from the current price of kr1,275.5.
The highest analyst share price target is kr2,700.00 ,and the lowest forecast is kr1,000.00. The average share price target represents 55.34% Increase from the current price of kr1,275.5.
What do analysts say about Genmab A/S?
Genmab A/S’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of Genmab A/S?
To buy shares of GB:0MGB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.